Enliven Therapeutics focuses on chronic myeloid leukemia drug as trial data nears

ca.finance.yahoo.com

Enliven Therapeutics is drawing investor attention ahead of updated trial data for its chronic myeloid leukemia drug. Updated Phase 1 ENABLE trial data for ELVN-001 will be presented at the European Hematology Association 2026 Congress on June 11, with a company webcast also scheduled. The company's stock has seen recent pullbacks but shows strong long-term momentum, trading at a Price to Book ratio above the broader sector but below its peers.


With a significance score of 1.1, this news ranks in the top 54% of today's 32742 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: